Načítá se...
New developments in the treatment of multiple myeloma – clinical utility of daratumumab
Multiple myeloma is a clonal disorder of plasma cells that is currently considered incurable. CD38 is a 46 kDa type II transmembrane glycoprotein that is highly expressed on myeloma cells. Daratumumab is a first in-class human IgG1 monoclonal antibody that targets CD38, and has antimyeloma effects t...
Uloženo v:
| Vydáno v: | Biologics |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5395289/ https://ncbi.nlm.nih.gov/pubmed/28442888 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BTT.S97633 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|